News
December 6, 2021 News
Award-Top Immunotherapy solution
providers in Europe 2021
November 25, 2021 News
Oblique Therapeutic’s interim report for
January – September 2021 (Q3 2021) is available.
November 18, 2021 Event
Oblique will be at the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
February 22- 24, 2022 Boston MA
November 16, 2021 News
Oblique Therapeutics welcomes Cecilia Larsson
as IRM - Investor Relations Manager position at the Gothenburg Office
November 16, 2021 News
Oblique Therapeutics welcomes Mats Lindskog
as CBO - Chief Business Officer working out from Stockholm Office
October 14, 2021 Event
Oblique Therapeutics presents its anti-Thioredoxin mAb program
at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.
October 6, 2021 News
New Press Article in Svenska Dagbladet
in the INNOVATIVA FÖRETAG edition - October 2021
October 5, 2021 News
Nobel Prize 2021 in Physiology or Medicine
for discoveries of receptors for temperature and touch.
October 4, 2021 News
Oblique Therapeutics announces that it has reached a key milestone
in its aKRAS antibody program and achieved validation of its Abiprot® platform.
September 15, 2021 News
Oblique Therapeutics: one of the 101 Top
Pharmaceutical Start Ups and Companies to follow in Sweden (2021).